Dynamic effects of China’s national volume-based procurement on generic drug consistency evaluation: An interrupted time series analysis
Xianli Ge, Xiaodong Liu, Weiyu Tian, Jing Peng, Mingyue Zhao, Yu Fang · 2026
Read Dynamic effects of China’s national volume-based procurement on generic drug consistency evaluation: An interrupted time series analysis by Xianli Ge, Xiaodong Liu, Weiyu Tian, Jing Peng, Mingyue Zhao, Yu Fang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0350141.txt.
Description
Xianli Ge and colleagues measured what happened after China tied bulk buying of generic drugs to a quality pass mark. Under the policy, listed generics must prove they match the original drug, and winners gain huge state orders at lower prices. Monthly counts of passed generics were tracked around the 2018 policy start, split by listed and unlisted drugs.
After 2018, passed generics grew by close to three extra drugs per month. Gains showed up both for listed drugs and for drugs outside the lists, which hints at spillover pressure across the industry. An earlier 2016 step showed no clear effect. Linking market access to proof of sameness, the data suggest, moves makers to certify quality.
Catalog record
| CREATOR | Xianli Ge, Xiaodong Liu, Weiyu Tian, Jing Peng, Mingyue Zhao, Yu Fang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36925 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |